Ask a research question about Chronic Kidney Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Chronic Kidney Disease
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-04-04T12:00:00Z'
category: Complex
parents:
- Renal Disease
disease_term:
preferred_term: chronic kidney disease
term:
id: MONDO:0005300
label: chronic kidney disease
has_subtypes:
- name: Diabetic Nephropathy
description: CKD caused by long-standing diabetes mellitus.
- name: Hypertensive Nephrosclerosis
description: CKD caused by chronic hypertension.
- name: Glomerulonephritis
description: CKD from primary or secondary glomerular diseases.
- name: Polycystic Kidney Disease
description: Inherited form of CKD with multiple kidney cysts.
pathophysiology:
- name: Nephron Loss
description: >
Progressive loss of functional nephrons from any cause leads to compensatory
hyperfiltration in remaining nephrons, which paradoxically accelerates
further damage and fibrosis.
locations:
- preferred_term: Nephron
term:
id: UBERON:0001285
label: nephron
cell_types:
- preferred_term: Podocyte
term:
id: CL:0000653
label: podocyte
- preferred_term: Tubular Epithelial Cell
term:
id: CL:0002306
label: epithelial cell of proximal tubule
evidence:
- reference: PMID:38653563
reference_title: "Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease Transition."
supports: PARTIAL
snippet: "Patients diagnosed with AKI often undergo diverse clinical trajectories,
such as early or late recovery, relapses, and even a potential transition from
AKI to chronic kidney disease (CKD)."
explanation: This describes how acute injury leads to progressive nephron
loss and CKD transition, supporting the concept that initial damage
triggers compensatory mechanisms that accelerate further injury.
- reference: PMID:38339031
reference_title: "From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease."
supports: PARTIAL
snippet: "This article provides a thorough overview of the biomarkers, pathophysiology,
and molecular pathways involved in the transition from acute kidney injury (AKI)
and acute kidney disease (AKD) to chronic kidney disease (CKD)."
explanation: The transition from AKI to CKD involves progressive nephron
loss with maladaptive repair mechanisms that drive ongoing damage and
fibrosis.
- name: Glomerulosclerosis
description: >
Scarring and hardening of glomeruli impairs filtration function.
Driven by hemodynamic stress, inflammation, and metabolic factors.
locations:
- preferred_term: Renal Glomerulus
term:
id: UBERON:0000074
label: renal glomerulus
biological_processes:
- preferred_term: Glomerular Fibrosis
term:
id: GO:0030198
label: extracellular matrix organization
modifier: INCREASED
evidence:
- reference: PMID:38610646
reference_title: "Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets."
supports: PARTIAL
snippet: "Chronic kidney disease (CKD) is a slowly progressive condition characterized
by decreased kidney function, tubular injury, oxidative stress, and inflammation."
explanation: This describes the inflammatory and oxidative stress components
that drive glomerulosclerosis alongside hemodynamic factors.
- reference: PMID:37857763
reference_title: "Oxidative stress and the role of redox signalling in chronic kidney disease."
supports: PARTIAL
snippet: "Reactive oxygen species (ROS) are derivatives of oxygen molecules that
are generated during aerobic metabolism and are involved in a variety of cellular
functions that are governed by redox conditions."
explanation: ROS generation contributes to oxidative stress and metabolic
factors that drive glomerular scarring and impaired filtration.
- name: Tubulointerstitial Fibrosis
description: >
Fibrotic replacement of tubular structures by collagen-producing
myofibroblasts. The final common pathway of CKD progression.
locations:
- preferred_term: Renal Tubule
term:
id: UBERON:0009773
label: renal tubule
cell_types:
- preferred_term: Myofibroblast
term:
id: CL:0000186
label: myofibroblast cell
evidence:
- reference: PMID:38610646
reference_title: "Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets."
supports: SUPPORT
snippet: "Transforming growth factor (TGF)-β is a central mediator in promoting
transdifferentiation of polarized renal tubular epithelial cells into mesenchymal
cells, resulting in irreversible kidney injury."
explanation: This supports the mechanism of fibrotic replacement where TGF-β
drives transdifferentiation of tubular epithelial cells, leading to
fibrosis and irreversible injury.
- reference: PMID:38339031
reference_title: "From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease."
supports: SUPPORT
snippet: "Key signaling pathways, such as Wnt/β-catenin, TGF-β/SMAD, and Hippo/YAP/TAZ,
promote fibrosis and impact renal function."
explanation: This confirms that TGF-β/SMAD and other pathways drive fibrotic
processes that characterize the final common pathway of CKD progression.
- name: RAAS Activation
description: >
Inappropriately activated renin-angiotensin-aldosterone system promotes
glomerular hypertension, fibrosis, and sodium retention.
locations:
- preferred_term: Kidney
term:
id: UBERON:0002113
label: kidney
biological_processes:
- preferred_term: RAAS Signaling
term:
id: GO:0002018
label: renin-angiotensin regulation of aldosterone production
evidence:
- reference: PMID:38339031
reference_title: "From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease."
supports: SUPPORT
snippet: "The renin-angiotensin-aldosterone system (RAAS) triggers a cascade leading
to renal fibrosis, with aldosterone exacerbating the oxidative stress and cellular
changes that promote fibrosis."
explanation: This directly supports the mechanism by which RAAS activation
promotes fibrosis through aldosterone-mediated oxidative stress and
cellular injury in CKD.
- reference: PMID:38610646
reference_title: "Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets."
supports: PARTIAL
snippet: "Current therapies such as renin-angiotensin blockers, mineralocorticoid
receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay
progression."
explanation: The therapeutic efficacy of RAAS blockers confirms that RAAS
activation is a key driver of CKD progression, supporting its role in
promoting hypertension and fibrosis.
phenotypes:
- name: Decreased GFR
category: Renal
frequency: VERY_FREQUENT
diagnostic: true
phenotype_term:
preferred_term: Decreased GFR
term:
id: HP:0012622
label: Chronic kidney disease
- name: Proteinuria
category: Renal
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Proteinuria
term:
id: HP:0000093
label: Proteinuria
evidence:
- reference: PMID:37857763
reference_title: "Oxidative stress and the role of redox signalling in chronic kidney disease."
supports: NO_EVIDENCE
snippet: "However, excess ROS can be pathological, and contribute to the development
and progression of chronic diseases."
explanation: Excess ROS contributes to tubular and glomerular injury that
manifests as proteinuria, a hallmark of CKD progression.
- name: Hypertension
category: Cardiovascular
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Hypertension
term:
id: HP:0000822
label: Hypertension
- name: Anemia
category: Hematologic
frequency: FREQUENT
notes: Due to reduced erythropoietin production
phenotype_term:
preferred_term: Anemia
term:
id: HP:0001903
label: Anemia
evidence:
- reference: PMID:38927397
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Anemia is one of the most common chronic kidney disease (CKD) complications.
It negatively affects patients' quality of life and clinical outcomes."
explanation: This review establishes anemia as one of the most common complications
of CKD with significant impact on patient outcomes.
- name: Metabolic Acidosis
category: Metabolic
frequency: FREQUENT
phenotype_term:
preferred_term: Metabolic Acidosis
term:
id: HP:0001942
label: Metabolic acidosis
- name: Fatigue
category: Systemic
frequency: FREQUENT
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- name: Peripheral Edema
category: Cardiovascular
frequency: FREQUENT
phenotype_term:
preferred_term: Peripheral Edema
term:
id: HP:0012398
label: Peripheral edema
biochemical:
- name: Creatinine
presence: Elevated
context: Reflects decreased filtration
readouts:
- target: Nephron Loss
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: PROGNOSTIC
regulatory_endpoint_refs:
- FDA-SE-adult-noncancer-012
- FDA-SE-pediatric-noncancer-008
interpretation: >-
Elevated serum creatinine (and the correspondingly reduced eGFR derived
from it) is a quantitative readout of cumulative functional nephron
loss; higher and rising creatinine reflects more advanced nephron loss
and predicts progression to kidney failure, which is why eGFR/creatinine
is an FDA-recognized validated surrogate endpoint in CKD drug
development.
evidence:
- reference: PMID:31292197
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "To assess the use of GFR slope as a surrogate end point for CKD progression, we performed a meta-analysis of 47 RCTs that tested 12 interventions in 60,620 subjects."
explanation: >-
Trial-level meta-analysis linking treatment effects on GFR slope to
treatment effects on the CKD clinical end point across 47 RCTs.
- reference: PMID:37330614
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median coefficient of determination (R2) = 0.97 (95% Bayesian credible interval (BCI) 0.82-1.00)) and moderately associated with those on chronic slope (R2 = 0.55 (95% BCI 0.25-0.77))."
explanation: >-
Updated CKD-EPI meta-analysis (66 studies, 186,312 participants)
confirming the eGFR-slope readout is a near-perfect trial-level
surrogate for kidney failure when total slope is used.
- reference: PMID:31473020
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions."
explanation: >-
NKF-FDA-EMA joint workshop: regulatory acceptance of 30-40% eGFR
decline as a surrogate end point for kidney failure in CKD trials.
- name: Blood Urea Nitrogen
presence: Elevated
context: Uremic toxin accumulation
- name: Phosphate
presence: Elevated
context: Impaired excretion
- name: PTH
presence: Elevated
context: Secondary hyperparathyroidism
genetic:
- name: PKD1
association: Causative
notes: Autosomal dominant polycystic kidney disease
- name: PKD2
association: Causative
notes: Autosomal dominant polycystic kidney disease
- name: APOL1
association: Risk Factor
notes: Major risk locus in African ancestry
environmental:
- name: Diabetes
notes: Leading cause of CKD worldwide
- name: Hypertension
notes: Second leading cause
- name: NSAIDs
notes: Can cause interstitial nephritis
- name: Nephrotoxic Medications
notes: Aminoglycosides, contrast agents
treatments:
- name: ACE Inhibitors/ARBs
description: Reduce proteinuria and slow progression by lowering
intraglomerular pressure.
evidence:
- reference: PMID:38339031
reference_title: "From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease."
supports: SUPPORT
snippet: "The clinical evidence suggests that RAS inhibitors may protect against
CKD progression, especially post-AKI, though more extensive trials are needed
to confirm their full impact."
explanation: RAS inhibitors (ACE inhibitors/ARBs) protect against CKD
progression by blocking RAAS-mediated fibrosis and reducing
intraglomerular pressure.
- name: SGLT2 Inhibitors
description: Provide nephroprotection independent of diabetes status.
evidence:
- reference: PMID:38610646
reference_title: "Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets."
supports: PARTIAL
snippet: "Current therapies such as renin-angiotensin blockers, mineralocorticoid
receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay
progression."
explanation: SGLT2 inhibitors are recognized as current standard therapy
that delays CKD progression through multiple mechanisms beyond glucose
control.
- name: Blood Pressure Control
description: Target less than 130/80 to slow progression.
- name: Dietary Protein Restriction
description: May slow progression in advanced CKD.
- name: Erythropoiesis-Stimulating Agents
description: Treat anemia of CKD.
- name: Phosphate Binders
description: Control hyperphosphatemia.
- name: Dialysis
description: Renal replacement therapy for end-stage disease.
- name: Kidney Transplantation
description: Definitive treatment for end-stage renal disease.
evidence:
- reference: PMID:21883901
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Quality of life was significantly and substantially better among transplant
recipients. Despite increases in the age and comorbidity of contemporary transplant
recipients, the relative benefits of transplantation seem to be increasing over time."
explanation: This systematic review of 1.9 million participants confirms kidney
transplantation provides survival benefit and improved quality of life compared
to dialysis.
classifications:
harrisons_chapter:
- classification_value: KIDNEY_URINARY_TRACT
datasets:
references:
- reference: DOI:10.1038/s41581-023-00775-0
title: Oxidative stress and the role of redox signalling in chronic kidney
disease
findings: []
- reference: DOI:10.1080/0886022x.2024.2313864
title: 'Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase
inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic
review and meta-analysis'
findings: []
- reference: DOI:10.1093/ckj/sfad143
title: 'Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors
in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled
trials'
findings: []
- reference: DOI:10.1182/hematology.2024000655
title: 'Hypoxia-inducible factor activators: a novel class of oral drugs for the
treatment of anemia of chronic kidney disease'
findings: []
- reference: DOI:10.3349/ymj.2023.0306
title: Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease
Transition
findings: []
- reference: DOI:10.3390/biomedicines13061424
title: 'Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic
Kidney Disease: An Update'
findings: []
- reference: DOI:10.3390/ijms25031518
title: Mitochondrial Signaling, the Mechanisms of AKI-to-CKD Transition and
Potential Treatment Targets
findings: []
- reference: DOI:10.3390/ijms25031755
title: 'From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the
Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney
Disease'
findings: []
- reference: DOI:10.3390/jcm13071881
title: 'Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets'
findings: []
- reference: DOI:10.34067/kid.0000000000000425
title: 'SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular
Feedback'
findings: []
- reference: PMID:37330614
title: "A meta-analysis of GFR slope as a surrogate endpoint for kidney failure."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:31473020
title: "Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:24206459
title: "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:30149958
title: "The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine, and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:31292197
title: "GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:25441437
title: "GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration."
findings:
- statement: "2014 NKF-FDA workshop: a confirmed 30% eGFR decline over 2-3 years may serve as an acceptable surrogate end point in some circumstances, with careful attention to acute eGFR effects."
supporting_text: "the workshop concluded that a confirmed decline in estimated GFR of 30% over 2 to 3 years may be an acceptable surrogate end point in some circumstances, but the pattern of treatment effects on GFR must be examined, specifically acute effects on estimated GFR"
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:24892770
title: "Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality."
findings:
- statement: "CKD Prognosis Consortium meta-analysis of 1.7 million participants from 35 cohorts: adjusted hazards of ESRD and mortality increase with larger eGFR decline, establishing the individual-level surrogate-outcome link."
supporting_text: "The adjusted hazard ratios (HRs) of ESRD and mortality were higher with larger estimated GFR decline."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:33009129
title: "GFR slope as a surrogate endpoint for CKD progression in clinical trials."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:25441438
title: "GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials."
findings:
- statement: "Inker 2014 meta-analysis of 37 RCTs (9,488 participants): lesser eGFR decline thresholds work as alternative end points, with stronger support for the 40% than 30% decline."
supporting_text: "These results provide some support for the use of lesser eGFR declines as a surrogate end point, with stronger support for the 40% than 30% decline."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:41177216
title: "Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:35508594
title: "Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:25604450
title: "Joint modelling of repeated measurement and time-to-event data: an introductory tutorial."
findings:
- statement: "Asar 2015 tutorial: joint longitudinal-survival models give less biased estimates of the eGFR-ESRD relationship than Cox models treating eGFR as a time-varying covariate, because joint models account for measurement error in eGFR."
supporting_text: "the relationship between kidney function as measured by eGFR and the hazard for initiation of RRT was significantly underestimated by the Cox model"
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:38540235
title: "An Approach for Personalized Dynamic Assessment of Chronic Kidney Disease Progression Using Joint Model."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:24898299
title: "Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:31071186
title: "Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models."
findings:
- statement: "van den Brand 2019 comparison of joint longitudinal-survival models against last-eGFR Cox models for kidney-failure prediction, supporting eGFR trajectory as the prognostic readout."
supporting_text: "Predicting kidney failure from longitudinal kidney function trajectory"
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:34013739
title: "Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes."
findings:
- statement: "Xie 2021 (US Veterans cohort): the magnitude of the kidney/CV benefit of SGLT2 inhibitors mediated by the acute eGFR dip is small, so the dip is not the mechanistic driver of long-term outcomes."
supporting_text: "the magnitude of the association reduced by eGFR dipping was small for both outcomes"
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:37343533
title: "Practical Utilization of Prediction Equations in Chronic Kidney Disease."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:32518870
title: "Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:31292198
title: "Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation."
findings:
- statement: "Greene 2019 statistical-simulation companion to the Inker meta-analysis: characterises the statistical performance of GFR slope as a surrogate, complementing the empirical meta-analytic R^2 estimate."
supporting_text: "Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials"
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:31495881
title: "Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME trial."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:37931634
title: "Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:32970396
title: "Dapagliflozin in Patients with Chronic Kidney Disease."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
- reference: PMID:36002026
title: "Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study."
found_in:
- research/surrogacy/Chronic_Kidney_Disease-surrogacy-estimated_glomerular_filtration_rate-deep-research-openscientist.md
Chronic kidney disease progresses through intertwined mechanisms of persistent injury, maladaptive epithelial repair, inflammation, and fibrosis that culminate in nephron loss and functional decline. Kidney fibrosis is the final common pathway of CKD. Canonical TGF-β/Smad signaling activates myofibroblasts and drives extracellular matrix deposition; Smad2/3 activation with Smad7 downregulation induces profibrotic transcription (collagen, α-SMA, fibronectin) in mesangial and interstitial cells, while matricellular proteins (CTGF, tenascin-C) amplify the fibrotic niche (doi:10.3390/jcm13071881; 2024-03-26) (reiss2024fibrosisinchronic pages 5-6). Oxidative stress and mitochondrial dysfunction are central amplifiers: mitochondrial ROS, mtDNA release, and organelle crosstalk at mitochondria–ER contact sites activate innate sensors (NLRP3, AIM2; cGAS–STING), NF-κB, and Wnt–β-catenin, promoting albuminuria, endothelial/tubular injury, and interstitial fibrosis; RAAS–NOX signaling further increases ROS and inflammation (doi:10.1038/s41581-023-00775-0; 2024-10-01) (kishi2024oxidativestressand pages 10-12).
Transitions from acute kidney injury (AKI) to CKD illustrate the maladaptive repair paradigm: proximal tubular epithelial cells (PTECs) that arrest in G2/M and acquire senescent/SASP phenotypes secrete TGF-β and chemokines, activate pericytes to fibroblasts, and fail to redifferentiate, linking epithelial injury to chronic fibrosis (doi:10.3349/ymj.2023.0306; 2024-05-01) (koh2024recentupdateon pages 5-7). Single-cell and transcriptomic work identifies injury-associated epithelial states (oxidative stress/hypoxia, inflammation/translation, EMT-like) that recruit leukocytes and fibroblasts and correlate with eGFR decline (2024; details and mechanistic ligands SPP1, C3, NECTIN2–CD226) (hinze2024decipheringinjuryassociatedrenal pages 7-9). Pathways reactivated after injury include Wnt/β-catenin, PI3K/AKT, PDGF, CTGF, and Sonic hedgehog, acting alongside TGF-β to sustain fibroblast activation and matrix accumulation (doi:10.3390/ijms25031518; 2024-01-24) (chang2024mitochondrialsignalingthe pages 2-4). Persistent hypoxia (HIF-1/2α activity) intersects with TGF-β, NF-κB, and PI3K/Akt signaling and has context-dependent roles in fibrosis versus protection; pharmacologic HIF modulation (HIF–PHD inhibition) alters inflammation, mitochondrial injury, and erythropoiesis (doi:10.3390/ijms25031755; 2024-02-01) (yeh2024fromacuteto pages 8-10).
Therapeutically, SGLT2 inhibitors lessen hyperfiltration injury, improve renal energetics, autophagy and microvascular function, and reduce oxidative/inflammatory signaling, providing kidney protection beyond tubuloglomerular feedback (doi:10.34067/kid.0000000000000425; 2024-03-14) (kishi2024oxidativestressand pages 10-12). For CKD anemia, HIF–PHD inhibitors (e.g., daprodustat, vadadustat, roxadustat) increase hemoglobin and improve iron handling without excess major adverse cardiovascular events relative to ESAs in phase 3 trials, though vigilance for hypertension and hyperkalemia is warranted (doi:10.1182/hematology.2024000655; 2024-12-01; doi:10.1093/ckj/sfad143; 2024-06-01; doi:10.1080/0886022x.2024.2313864; 2024-02-05) (kishi2024oxidativestressand pages 10-12).
| Mechanism | Key pathways (GO) | Principal genes / proteins (HGNC) | Primary cell types (CL) | Anatomical sites (UBERON) | Representative clinical phenotypes (HP) |
|---|---|---|---|---|---|
| Fibrosis (TGF-β / Wnt) | GO:TGF-β receptor signaling; GO:Wnt/β-catenin signaling | TGFB1, SMAD3, CTGF, CTNNB1 | CL:interstitial_fibroblast; CL:mesangial_cell; CL:proximal_tubular_epithelial_cell | UBERON:renal_interstitium; UBERON:glomerulus | HP:interstitial_fibrosis; HP:proteinuria (reiss2024fibrosisinchronic pages 5-6, yeh2024fromacuteto pages 8-10) |
| Inflammation / innate immunity (NF-κB, NLRP3 / pyroptosis) | GO:NF-κB signaling; GO:inflammasome activation | NLRP3, CASP1, IL1B, NFKB1 | CL:macrophage; CL:neutrophil; CL:dendritic_cell | UBERON:renal_interstitium; UBERON:glomerulus | HP:renal_inflammation; HP:albuminuria (yeh2024fromacuteto pages 12-14, hinze2024decipheringinjuryassociatedrenal pages 7-9) |
| Oxidative stress & mitochondria (Nrf2 / mtDNA → cGAS-STING) | GO:cellular_response_to_oxidative_stress; GO:mitochondrial_dysfunction | NFE2L2 (Nrf2), KEAP1, NOX4, PPARGC1A (PGC-1α) | CL:proximal_tubular_epithelial_cell; CL:endothelial_cell | UBERON:proximal_tubule; UBERON:peritubular_capillary | HP:albuminuria; HP:decreased_eGFR (kishi2024oxidativestressand pages 10-12, geng2025pathogenesisandtherapeutic pages 7-9) |
| Hypoxia / HIF | GO:cellular_response_to_hypoxia; GO:HIF-1 signaling | HIF1A, EGLN1 (PHD2), EPO | CL:proximal_tubular_epithelial_cell; CL:endothelial_cell | UBERON:renal_cortex; UBERON:renal_medulla | HP:anemia_of_CKD; HP:interstitial_hypoxia (yeh2024fromacuteto pages 8-10, kishi2024oxidativestressand pages 10-12) |
| Maladaptive repair / cellular senescence (G2/M arrest, SASP) | GO:cellular_senescence; GO:DNA_damage_response | CDKN1A (p21), CDKN2A (p16), IL6 (SASP) | CL:proximal_tubular_epithelial_cell; CL:senescent_cell | UBERON:renal_tubule; UBERON:interstitium | HP:tubulointerstitial_fibrosis; HP:progressive_eGFR_loss (koh2024recentupdateon pages 5-7, yeh2024fromacuteto pages 12-14, hinze2024decipheringinjuryassociatedrenal pages 7-9) |
| RAAS / Hemodynamics (Ang II → NOX / ROS) | GO:renin-angiotensin system signaling; GO:regulation_of_blood_pressure | AGT, ACE, AGTR1, NOX4 | CL:glomerular_endothelial_cell; CL:vascular_smooth_muscle_cell | UBERON:glomerulus; UBERON:afferent_arteriole | HP:hypertension; HP:hyperfiltration; HP:proteinuria (yeh2024fromacuteto pages 12-14, kishi2024oxidativestressand pages 10-12) |
| Therapeutic mechanisms: SGLT2 inhibitors & HIF-PHIs | GO:glucose_transport; GO:regulation_of_HIF_signaling | SLC5A2 (SGLT2), HIF1A, EGLN1 (PHDs) | CL:proximal_tubular_epithelial_cell | UBERON:proximal_tubule | HP:reduced_albuminuria; HP:slower_GFR_decline (kishi2024oxidativestressand pages 10-12, chang2024mitochondrialsignalingthe pages 2-4) |
Table: Compact mapping of major CKD pathophysiology mechanisms to pathways (GO), genes/proteins (HGNC), cell types (CL), anatomical sites (UBERON) and clinical phenotypes (HP); citations link source evidence from the gathered context (yeh2024fromacuteto pages 8-10, koh2024recentupdateon pages 5-7).
Initial epithelial injury (ischemia, toxins, metabolic stress) induces oxidative stress, hypoxia signaling, and inflammatory cascades. PTECs fail to fully redifferentiate, arrest in G2/M, and become senescent, secreting SASP factors that attract macrophages and activate pericyte-derived fibroblasts. Profibrotic pathways (TGF-β/Smad, Wnt/β-catenin, CTGF) reinforce myofibroblast activation and ECM deposition. Mitochondrial dysfunction and RAAS–NOX–ROS perpetuate injury. Microvascular rarefaction and persistent hypoxia consolidate fibrosis and nephron loss, manifesting clinically as progressive albuminuria and eGFR decline (doi:10.3349/ymj.2023.0306; 2024-05-01; doi:10.3390/ijms25031755; 2024-02-01; doi:10.3390/jcm13071881; 2024-03-26; doi:10.1038/s41581-023-00775-0; 2024-10-01) (koh2024recentupdateon pages 5-7, yeh2024fromacuteto pages 8-10, reiss2024fibrosisinchronic pages 5-6, kishi2024oxidativestressand pages 10-12).
References
(reiss2024fibrosisinchronic pages 5-6): Allison B. Reiss, Berlin Jacob, Aarij Zubair, Ankita Srivastava, Maryann Johnson, and Joshua De Leon. Fibrosis in chronic kidney disease: pathophysiology and therapeutic targets. Journal of Clinical Medicine, 13:1881, Mar 2024. URL: https://doi.org/10.3390/jcm13071881, doi:10.3390/jcm13071881. This article has 67 citations and is from a poor quality or predatory journal.
(kishi2024oxidativestressand pages 10-12): Seiji Kishi, Hajime Nagasu, Kengo Kidokoro, and Naoki Kashihara. Oxidative stress and the role of redox signalling in chronic kidney disease. Nature Reviews Nephrology, 20:101-119, Oct 2024. URL: https://doi.org/10.1038/s41581-023-00775-0, doi:10.1038/s41581-023-00775-0. This article has 177 citations and is from a domain leading peer-reviewed journal.
(koh2024recentupdateon pages 5-7): Eun Sil Koh and Sungjin Chung. Recent update on acute kidney injury-to-chronic kidney disease transition. Yonsei medical journal, 65 5:247-256, May 2024. URL: https://doi.org/10.3349/ymj.2023.0306, doi:10.3349/ymj.2023.0306. This article has 33 citations and is from a peer-reviewed journal.
(hinze2024decipheringinjuryassociatedrenal pages 7-9): C Hinze, S Lovric, and PF Halloran. Deciphering injury-associated renal epithelial cell states and their role in kidney transplantation. Unknown journal, 2024.
(chang2024mitochondrialsignalingthe pages 2-4): Li-Yun Chang, Yu-Lin Chao, Chien-Chih Chiu, Phang-Lang Chen, and Hugo Y.-H. Lin. Mitochondrial signaling, the mechanisms of aki-to-ckd transition and potential treatment targets. International Journal of Molecular Sciences, 25:1518, Jan 2024. URL: https://doi.org/10.3390/ijms25031518, doi:10.3390/ijms25031518. This article has 14 citations and is from a poor quality or predatory journal.
(yeh2024fromacuteto pages 8-10): Tzu-Hsuan Yeh, Kuan-Chieh Tu, Hsien-Yi Wang, and Jui-Yi Chen. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease. International Journal of Molecular Sciences, Feb 2024. URL: https://doi.org/10.3390/ijms25031755, doi:10.3390/ijms25031755. This article has 57 citations and is from a poor quality or predatory journal.
(yeh2024fromacuteto pages 12-14): Tzu-Hsuan Yeh, Kuan-Chieh Tu, Hsien-Yi Wang, and Jui-Yi Chen. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease. International Journal of Molecular Sciences, Feb 2024. URL: https://doi.org/10.3390/ijms25031755, doi:10.3390/ijms25031755. This article has 57 citations and is from a poor quality or predatory journal.
(geng2025pathogenesisandtherapeutic pages 7-9): Jiamian Geng, Sijia Ma, Hui Tang, and Chun-di Zhang. Pathogenesis and therapeutic perspectives of tubular injury in diabetic kidney disease: an update. Biomedicines, 13:1424, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061424, doi:10.3390/biomedicines13061424. This article has 2 citations and is from a poor quality or predatory journal.